ELI LILLY: PLANS TO INITIATE PHASE 3 STUDIES OF ELORATZP CO-FORMULATION PRODUCT BY 2026 END USING OPTIMIZED ESCALATION SCHEDULE

Reuters · 3d ago

Please log in to view news